4. Sun S-Y, H Fu, Khuri FR. Targeting Mtor Signaling for Lung Cancer Therapy. J Thor Oncol

IMPACT

Articles: 1. Hajitou A, Trepel M, Lilly CE, Soghomonyan S, Alauddin MM, Marini III FC, Restel BH, Ozawa MG, Moya CA, Rangel R, Sun Y, Zaoui K, Schmidt M, Kalle CV, Weitzman MD, Gelovani JG, Pasqualini R, Arap W. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 125:385-98, 2006. 2. Kolonin MG, Bover L, Sun J, Zurita AJ, Do KA, Lahdenranta J, Cardo-Vila M, Giordano RJ, Jaalouk DE, Ozawa MG, Moya CA, Souza GR, Staquicini FI, Kunyiasu A, Scudiero DA, Holbeck SI, Sausville EA, Arap W, Pasqualini Renata. Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res (Priority Report) 66: 34-40, 2006. 3. Kong M, Lee JJ. A generalized response surface model with varying relative potency for assessing drug interaction. Biometrics (in press), 2006. 4. Sun S-Y, H Fu, Khuri FR. Targeting mTOR signaling for lung cancer therapy. J Thor Oncol 1: 109-11, 2006. 5. Sun S-Y, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mTOR inhibition. Cancer Res (Priority Report) 65:7052-8, 2005. 6. Yuan P, Temam S, Ek-Naggar A, Zhou X, Liu D, Lee JJ, Mao L. Overexpression of Podoplanin in oral cancer and its association with poor clinical outcome. Cancer June 27, 2006 (epub ahead of print).

Abstracts: 1. Alexander V. Prokhorov, Ellen R. Gritz, Nancy Stancic Luca, Salma Marani, Mario Luca, Jeff McLaughlin, Tim Maloney, Michael Stovall. Project TALK (Teens and Young Adults Acquiring Lung Cancer Knowledge. Science Day, The University of Texas M.D. Anderson Cancer Center, Houston, 2005. 2. Behrens C, Wistuba II, Feng L, Lee JJ, Hong WK, Lotan R. Expression of Fibroblast Growth Factor and its Receptors in Premalignant and Malignant Human Lung Tissues. Proc AACR 47, 2006. 3. Massarelli E, Zhou X, Ozburn N, Wislez M, Bekele BN, Roth JA, O’Reilly M, Hong WK, Kurie J,. Herbst RS, Wistuba II. TGF-α and phosphorylated EGFR protein levels impact the survival of patients with stage I-IIIA Non Small Cell Lung Cancer. Proc AACR 47, 2006. 4. Munshi A, Tanaka T, Hobbs ML, Meyn RE. Radiosensitization of human melanoma cells by sorafenib (BAY 43-9006), a multi-kinase inhibitor. Proc AACR 47, 2006. 5. Musaffe T, Colella T, Rhee J, Zhang B, Tsavachidis S, Baggerly K A, Krahe, R. Integrated genomic and transcriptomic profiling of oral squamous cell carcinoma cell lines and primary tumors identifies novel tumorigenesis-associated genes. AACR Oncogenomics Conference, San Diego, CA, February 2-6, 2005. 6. Musaffe T, Colella T, Rhee J, Zhang B, Tsavachidis S, Baggerly KA, Krahe R. Integrated genomic and transcriptomic profiling of oral squamous cell carcinoma cell lines and primary tumors identifies novel tumorigenesis-associated genes. The Annual University of Texas M. D. Anderson Cancer Center Trainee Recognition Day, 2005. 7. Paternoster L, Munshi A, Meyn RE. Role of MDM2 in DNA repair. Proc AACR 47, 2006. 8. Richards K., Colella S, Baggerly KA, Tsavachidis Lang JC, Schuller DE, Krahe R. Human papilloma virus (HPV)-positive head and neck cancers are genetically distinct at both the DNA and RNA level, as revealed by wide-scale genomic analyses. Platform presentation at 41st ASCO Annual Meeting, Orlando, FL, May 13-17, 2005. 9. Richards KL, Colella S, Baggerly KA, Tsavachidis Lang JC, Schuller DE, Krahe R. Genomic and transcriptomic profiling of Human Papilloma Virus (HPV)-positive head and neck squamous cell carcinomas (HNSCC) identifies a genetically distinct subgroup of head and neck cancers. AACR Oncogenomics Conference, San Diego, CA, February 2- 6, 2005. 10. Wistuba II. Analysis of EGFR abnormalities in the sequential pathogenesis and progression of lung adenocarcinoma. Proc AACR 47, 2006. 11. Yuan P, Temam S, Ei-Naggar A, Zhou X, Lee JJ, Mao L. Podoplanin is overexpressed in head and neck squamous cell carcinomas (HNSCC) and is associated with poor clinical outcome. Proc AACR 47, 2006.